The effect of canagliflozin, a sodium glucose cotransporter 2 inhibitor, on glycemic end points assessed by continuous glucose monitoring and patient-reported outcomes among people with type 1 diabetes

Diabetes Care

Volumn 40, Issue 2, 2017, Pages 171-180

  Rodbard, Helena W ^a   Peters, Anne L ^b   Slee, April ^c   Cao, Anjun ^d   Traina, Shana B ^d   Alba, Maria ^d  

^a Endocrine and Metabolic Consultants   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Axio Research   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; GLUCOSE; INSULIN; PLACEBO; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ADD ON THERAPY; ADULT; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CONFERENCE PAPER; CONTINUOUS INFUSION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GLYCEMIC VARIABILITY; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MULTICENTER STUDY; PATIENT SATISFACTION; PATIENT-REPORTED OUTCOME; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; AGED; ANTAGONISTS AND INHIBITORS; BIOASSAY; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DOSE RESPONSE; FOLLOW UP; METABOLISM; MIDDLE AGED; STATISTICAL MODEL;

ADULT; AGED; BLOOD GLUCOSE SELF-MONITORING; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LOGISTIC MODELS; MALE; MIDDLE AGED; PATIENT REPORTED OUTCOME MEASURES; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85011650209     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-1353     Document Type: Conference Paper

References (46)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329: 977-986
2. Nathan DM, Cleary PA, Backlund JY, et al.; Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653
3. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care 1984;7: 188-199
4. Galloway JA, Spradlin CT, Nelson RL, Wentworth SM, Davidson JA, Swarner JL. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care 1981;4:366-376
5. Sindelka G, Heinemann L, Berger M, Frenck W, Chantelau E. Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia 1994;37:377-380
6. Chiang JL, Kirkman MS, Laffel LM, Peters AL; Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 2014;37:2034-2054
7. Martyn-Nemeth P, Schwarz Farabi S, Mihailescu D, Nemeth J, Quinn L. Fear of hypoglycemia in adults with type 1 diabetes: impact of therapeutic advances and strategies for prevention-a review. J Diabetes Complications 2016;30:167-177
8. Anderbro T, Gonder-Frederick L, Bolinder J, et al. Fear of hypoglycemia: relationship to hypoglycemic risk and psychological factors. Acta Diabetol 2015;52:581-589
9. Willis WD, Diago-Cabezudo JI, Madec-Hily A, Aslam A. Medical resource use, disturbance of daily life and burden of hypoglycemia in insulintreated patients with diabetes: results from a European online survey. Expert Rev Pharmacoecon Outcomes Res 2013;13:123-130
10. Tumminia A, Sciacca L, Frittitta L, et al. Integrated insulin pump therapy with continuous glucose monitoring for improved adherence: technology update. Patient Prefer Adherence 2015;9:1263-1270
11. Pickup JC, Ford Holloway M, Samsi K. Realtime continuous glucose monitoring in type 1 diabetes: a qualitative framework analysis of patient narratives. Diabetes Care 2015;38: 544-550
12. Kilpatrick ES, Rigby AS, Goode K, Atkin SL. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia 2007; 50:2553-2561
13. Cox DJ, Kovatchev BP, Julian DM, et al. Frequency of severe hypoglycemia in insulin-dependent diabetes mellitus can be predicted from selfmonitoring blood glucose data. J Clin Endocrinol Metab 1994;79:1659-1662
14. Ceriello A, Kilpatrick ES. Glycemic variability: both sides of the story. Diabetes Care 2013; 36(Suppl. 2):S272-S275
15. Bragd J, Adamson U, Bäcklund LB, Lins PE, Moberg E, Oskarsson P. Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade? Diabetes Metab 2008;34:612-616
16. Bergenstal RM. Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers! Diabetes Care 2015;38:1615-1621
17. Kovatchev B, Cobelli C. Glucose variability: timing, risk analysis, and relationship to hypoglycemia in diabetes. Diabetes Care 2016;39:502-510
18. Ayano-Takahara S, Ikeda K, Fujimoto S, et al. Glycemic variability is associated with quality of life and treatment satisfaction in patients with type 1 diabetes. Diabetes Care 2015;38:e1-e2
19. Barbosa CD, Balp MM, Kulich K, Germain N, Rofail D. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence 2012;6:39-48
20. Biderman A, Noff E, Harris SB, Friedman N, Levy A. Treatment satisfaction of diabetic patients: what are the contributing factors? Fam Pract 2009;26:102-108
21. Redekop WK, KoopmanschapMA, Stolk RP, Rutten GE, Wolffenbuttel BH, Niessen LW. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 2002;25:458-463
22. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033-1046
23. Rosenthal N, Meininger G, Ways K, et al. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann N Y Acad Sci 2015;1358:28-43
24. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012;14:539-545
25. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes ObesMetab 2011;13:669-672
26. Polidori D, Sha S, Ghosh A, Plum-Mörschel L, Heise T, Rothenberg P. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozintreated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013;98:E867-E871
27. Argento NB, Nakamura K. Glycemic effects of SGLT-2 inhibitor canagliflozin in type 1 diabetes using Dexcom G4 Platinum CGM. Endocr Pract 2016;22:315-322
28. Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes mellitus. Diabetes Care 2015;38:2258-2265
29. Peters AL, Henry RR, Thakkar P, Tong C, Alba M. Diabetic ketoacidosiswith canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 1 diabetes. Diabetes Care 2016;39:532-538
30. Howorka K, Pumprla J, Schlusche C, Wagner-Nosiska D, Schabmann A, Bradley C. Dealing with ceiling baseline treatment satisfaction level in patients with diabetes under flexible, functional insulin treatment: assessment of improvements in treatment satisfaction with a new insulin analogue. Qual Life Res 2000;9:915-930
31. Bradley C. The diabetes treatment satisfaction questionnaire: DTSQ. In Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice. Bradley C, Ed. Abingdon, U.K., Routledge, 1994, p. 111-132
32. Bradley C. Feedback on the FDA's February 2006 draft guidance on patient reported outcome (PRO) measures from a developer of PRO measures. Health Qual Life Outcomes 2006;4:78
33. Bradley C, Gamsu DS. Guidelines for encouraging psychological well-being: report of a working group of theWorld Health Organization Regional Office for Europe and International Diabetes Federation European Region St Vincent Declaration Action Programme for Diabetes. Diabet Med 1994;11:510-516
34. Baghurst PA. Calculating the mean amplitude of glycemic excursion fromcontinuous glucose monitoring data: an automated algorithm. Diabetes Technol Ther 2011;13:296-302
35. Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care 2015;38:412-419
36. Imai K, Tingley D, Yamamoto T. Advances in Social Science Research Using R. New York, Springer-Verlag, 2010
37. VanderWeele TJ. Explanation in Causal Inference: Methods for Mediation and Interaction. New York, Oxford University Press, 2015
38. Perkins BA, Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014;37:1480-1483
39. Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 2015;38:1181-1188
40. Famulla S, Pieber TR, Eilbracht J, et al. Empagliflozin (EMPA) decreases glucose exposure and variability in patients with type 1 diabetes (T1DM): continuous glucose monitoring (CGM) data (EASE-1). Diabetes 2015;64:A235-A382
41. Perkins BA, Cherney DZ, Soleymanlou N, et al. Diurnal glycemic patterns during an 8-week open-label proof-of-concept trial of empagliflozin in type 1 diabetes. PLoS One 2015;10:e0141085
42. Ashwell SG, Bradley C, Stephens JW, Witthaus E, Home PD. Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes. Diabetes Care 2008;31:1112-1117
43. Traina SB, Slee A, Woo S, Canovatchel W. The importance of weight change experiences for performance of diabetes self-care: a patientcentered approach to evaluating clinical outcomes in type 2 diabetes. Diabetes Ther 2015;6:611-625
44. Shikiar R, Rentz AM. Satisfaction with medication: an overview of conceptual, methodologic, and regulatory issues. Value Health 2004;7:204-215
45. Nam S, Chesla C, Stotts NA, Kroon L, Janson SL. Barriers to diabetes management: patient and provider factors. Diabetes Res Clin Pract 2011;93:1-9
46. Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the AmbulatoryGlucose Profile (AGP). Diabetes Technol Ther 2013;15:198-211